- Home
- EQR vs BIIB Comparison
EQR vs BIIB Comparison
Compare EQR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQR
- BIIB
- Stock Information
- Founded
- EQR 1993
- BIIB 1978
- Country
- EQR United States
- BIIB United States
- Employees
- EQR N/A
- BIIB N/A
- Industry
- EQR Real Estate Investment Trusts
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- EQR Real Estate
- BIIB Health Care
- Exchange
- EQR Nasdaq
- BIIB Nasdaq
- Market Cap
- EQR 26.7B
- BIIB 18.8B
- IPO Year
- EQR 1993
- BIIB 1991
- Fundamental
- Price
- EQR $66.78
- BIIB $125.00
- Analyst Decision
- EQR Buy
- BIIB Buy
- Analyst Count
- EQR 15
- BIIB 27
- Target Price
- EQR $79.00
- BIIB $188.17
- AVG Volume (30 Days)
- EQR 1.9M
- BIIB 1.3M
- Earning Date
- EQR 07-28-2025
- BIIB 07-31-2025
- Dividend Yield
- EQR 4.11%
- BIIB N/A
- EPS Growth
- EQR 8.50
- BIIB 26.39
- EPS
- EQR 2.62
- BIIB 10.12
- Revenue
- EQR $3,010,100,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- EQR $5.13
- BIIB N/A
- Revenue Next Year
- EQR $4.28
- BIIB N/A
- P/E Ratio
- EQR $25.74
- BIIB $12.41
- Revenue Growth
- EQR 3.81
- BIIB 1.59
- 52 Week Low
- EQR $59.41
- BIIB $110.04
- 52 Week High
- EQR $78.84
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- EQR 34.93
- BIIB 45.14
- Support Level
- EQR $65.19
- BIIB $123.21
- Resistance Level
- EQR $69.87
- BIIB $129.27
- Average True Range (ATR)
- EQR 1.21
- BIIB 3.00
- MACD
- EQR -0.36
- BIIB -0.77
- Stochastic Oscillator
- EQR 15.54
- BIIB 21.06
About EQR Equity Residential of Beneficial Interest
Equity Residential owns a portfolio of 312 apartment communities with over 84,000 units and is developing two additional properties with 655 units. The company focuses on owning large, high-quality properties in the urban and suburban submarkets of Southern California, San Francisco, Washington, D.C., New York, Seattle, and Boston.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.